Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: education

AI Safety Expert: Nobody Has A Plan For What’s Coming With AGI

According to Eliezer Yudkowsky, one of the leading thinkers in the field of AI safety and AGI alignment, the dangers associated with the development of such systems do not stop at job replacement, propaganda, and other problems related to social and economic consequences. Rather, the main threat associated with highly developed superintelligent artificial intelligence, as Yudkowsky emphasizes, is the existence of the danger that humanity would create such machines but be unable to control them properly. The author suggests the possibility that such artificial intelligence could use its biotechnological capabilities to cause disaster for the entire civilization, rapidly reach nanotechnological development milestones, and outmaneuver all attempts by humans to regulate its activities.

In the present day, as the development of artificial general intelligence progresses, there are several key questions regarding it that need to be discussed thoroughly. Thus, this fascinating interview with the noted expert covers many of these issues related to AGI and the rapid pace of research in the sphere. According to Yudkowsky, the development of ever more intelligent systems without researching how to make them safe is a serious mistake, and people should think carefully before trying this dangerous experiment again.

📚 Sources cited in this video:

OpenAI, Introducing Superalignment.
https://openai.com/index/introducing–…

  • Eliezer Yudkowsky, If Anyone Builds It, Everyone Dies

https://time.com/6266923/ai-eliezer-y…

  • Center for AI Safety

https://www.safe.ai

  • Future of Life Institute, AI Risk Resources

https://futureoflife.org ⚠️ DISCLAIMER: This channel provides AI commentary and analysis for educational and informational purposes only. Views expressed by guests are their own and do not represent the positions of any company or institution. We encourage viewers to consult multiple sources and form their own conclusions. #ai #agi #artificialintelligence.

Eliezer Yudkowsky, If Anyone Builds It, Everyone Dies.
https://time.com/6266923/ai-eliezer-y…

Center for AI Safety.

Continue reading “AI Safety Expert: Nobody Has A Plan For What’s Coming With AGI” | >

Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome

Early intervention and environmental optimization have been central to management of Down syndrome (DS) and much of current treatment is still focused in strategies that involve early education plans. This approach has provided significant improvements for Down syndrome but it is not providing a full success. The discovery of an increasing number of genes and molecular pathways linked to intellectual disability and involving a range of synaptic and plasticity-related mechanisms has open new treatment opportunities that focus on targeted treatments boosting neural plasticity. We here discuss some of these approaches, focusing on the effects of environmental enrichment and on the discovery of pharmacological therapies showing beneficial effects even in some clinical trials in adult individuals with Down syndrome. Targeting plasticity impairments in DS is thus a promising strategy to promote cellular mechanisms involved in learning and memory within key cognitive brain region and could lead to improved connectivity.

Keywords: EGCG; Environ-mimetic drugs; Environmental enrichments; Epigenetics; Neuronal plasticity.

© 2020 Elsevier B.V. All rights reserved.

Ex-Google CEO: What Artificial Superintelligence Will Actually Look Like w/ Eric Schmidt & Dave B

Get access to metatrends 10+ years before anyone else — https://qr.diamandis.com/metatrends.

Eric Schmidt is the former CEO of Google.

Dave Blundin is the founder of Link Ventures.

Chapters.

00:00 — The Rise of Digital Superintelligence.
09:26 — AI and Energy: The Power Behind Progress.
18:34 — The Future of Work: AI’s Impact on Jobs.
28:02 — Navigating the AI Landscape: Opportunities and Risks.
37:13 — The Role of Education in an AI-Driven World.
46:41 — The Ethics of AI: Balancing Innovation and Responsibility.
56:12 — The Future of Creativity: AI in Arts and Media.

–

Continue reading “Ex-Google CEO: What Artificial Superintelligence Will Actually Look Like w/ Eric Schmidt & Dave B” | >

A Stanford Physicist Found the Actual Reason We Age. And He Says It Can Be Fixed | Tom Benson Ep 234

I had Tom Benson, CEO of Mitrix on to discuss mitochondrial transplantation. We covered what mitochondria are, the discovery that your body is constantly delivering fresh mitochondria through your bloodstream (people didn’t know that mitochondria were transferred outside the cell until recently!), why we age, what kills mitochondria (stress, smoking, radiation, chemotherapy and certain antibiotics like fluoroquinolones, psych meds), why COVID destroys mitochondria and what that means for long COVID, the Alzheimer’s and Parkinson’s brain tissue regeneration research their company has already done in mice, what mitochondrial transplantation actually is and how it has already been used in pediatric heart surgery, what a bioreactor growing mitochondria for personal use might look like, and more.

Find Tom at mitrix.bio (http://mitrix.bio/).

Mitochondrial Transplantation Conference: • 2025 Mitochondrial Transplantation Conference.

For a high quality education and community consider enrolling in Peterson Academy: https://petersonacademy.com/

—Research Sites—
Newsletter/website: https://mikhailapeterson.com.
Fuller Research Foundation: https://fullerresearch.org.
Lion Diet: https://liondiet.com.
Biotoxin: https://biotoxin.com.
Prescribed-Harm: https://prescribed-harm.com.

—Socials—

Continue reading “A Stanford Physicist Found the Actual Reason We Age. And He Says It Can Be Fixed | Tom Benson Ep 234” | >

E.W. Dijkstra Archive: On the cruelty of really teaching computing science (EWD 1036)

For Dijkstra, programming was closer to mathematics than to a craft. The goal wasn’t to “get a feel” for code. The goal was to reason about it rigorously, to understand why it works before discovering whether it works.

The second part of this talk pursues some of the scientific and educational consequences of the assumption that computers represent a radical novelty. In order to give this assumption clear contents, we have to be much more precise as to what we mean in this context by the adjective “radical”. We shall do so in the first part of this talk, in which we shall furthermore supply evidence in support of our assumption.

The usual way in which we plan today for tomorrow is in yesterday’s vocabulary. We do so, because we try to get away with the concepts we are familiar with and that have acquired their meanings in our past experience. Of course, the words and the concepts don’t quite fit because our future differs from our past, but then we stretch them a little bit. Linguists are quite familiar with the phenomenon that the meanings of words evolve over time, but also know that this is a slow and gradual process.

It is the most common way of trying to cope with novelty: by means of metaphors and analogies we try to link the new to the old, the novel to the familiar. Under sufficiently slow and gradual change, it works reasonably well; in the case of a sharp discontinuity, however, the method breaks down: though we may glorify it with the name “common sense”, our past experience is no longer relevant, the analogies become too shallow, and the metaphors become more misleading than illuminating. This is the situation that is characteristic for the “radical” novelty.

BREAKTHROUGH CHOLESTEROL CURE Lowers LDL For Life

New LDL Drug Could Cure Heart Disease. Eli Lilly published Phase 1 data in the New England Journal of Medicine showing that a single IV infusion of a gene editing therapy called VERVE-102 lowered LDL cholesterol permanently. Well… the effect held for at least 18 months. Longevity Twitter immediately called it the cure for heart disease. The science is real. The hype is getting ahead of what the paper actually says. This episode walks through the Phase 1 Heart-2 trial — the data, the base-editing mechanism (which is NOT CRISPR), the one safety event nobody’s talking about, and how Eli Lilly’s CEO is publicly thinking about pricing a one-and-done cure.

HUME BODY POD DISCOUNT UP TO 50% OFF:
Code: LSN20
https://humehealth.com/pages/hume-bod… Latte: https://longevitylatte.shop TIMESTAMPS 0:00 — Cold Open 1:41 — Sponsor: Hume Body Pod 2:53 — Intro: The Cholesterol Paradox 4:48 — How Statins Work 5:36 — PCSK9 Targeting 7:38 — How VERVE-102 Works 9:16 — The Results 12:16 — Other Drugs and Pricing 15:12 — Natural Alternatives 17:42 — Other One and Done Drugs 18:40 — Longevity Latte SOURCES & LINKS NEJM paper (Vafai, Täubel, Patel, Kathiresan et al.): https://www.nejm.org/doi/full/10.1056… Eli Lilly press release on Phase 1 Heart-2 data: https://www.prnewswire.com/news-relea… ClinicalTrials.gov Heart-2 trial entry (NCT06164730): https://clinicaltrials.gov/study/NCT0… Verve Therapeutics FDA Fast Track designation announcement: https://vervetx.gcs-web.com/news-rele… Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): https://www.nejm.org/doi/abs/10.1056/.… Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: • Dave Ricks, CEO of Eli Lilly, on GLP-1s an… FOURIER trial (evolocumab cardiovascular outcomes): https://www.nejm.org/doi/full/10.1056… ODYSSEY OUTCOMES trial (alirocumab cardiovascular outcomes): https://www.nejm.org/doi/full/10.1056… PCSK9 LoF and diabetes (Mendelian randomization, Lancet Diabetes & Endocrinology): https://www.thelancet.com/journals/la… PCSK9 inhibition and diabetes risk review: https://pmc.ncbi.nlm.nih.gov/articles… StatPearls overview of PCSK9 inhibitors: https://www.ncbi.nlm.nih.gov/books/NB… Sardinia cholesterol paradox study: https://pmc.ncbi.nlm.nih.gov/articles… Statin pleiotropic effects review (mevalonate pathway): https://www.ncbi.nlm.nih.gov/pmc/arti… Berberine as a nature-made PCSK9 inhibitor review: https://www.ncbi.nlm.nih.gov/pmc/arti… Berberine for dyslipidaemias meta-analysis: https://pubmed.ncbi.nlm.nih.gov/30466… Pomegranate juice, carotid IMT, and LDL oxidation (Aviram 3-year study): https://www.clinicalnutritionjournal… LATEST EXCLUSIVE INTERVIEW: [Ariel Garten / Muse headset interview YouTube URL] ABOUT LONGEVITY SCIENCE NEWS Longevity Science News covers the latest breakthroughs in anti-aging research, regenerative medicine, longevity biotech, and the science of extending human healthspan and lifespan. Hosted by Emmett Short. Disclaimer: This video is for educational and informational purposes only and does not constitute medical advice. Consult a qualified clinician before making health or treatment decisions. EXCLUSIVE INTERVIEWS & BONUS CONTENT Patreon: https://patreon.com/u29506604?utm_med… YT Membership: / @longevitysciencenews PRODUCTION CREDITS Executive Producer – Keith Comito Host, Producer, Writer – Emmett Short.

Longevity Latte:
https://longevitylatte.shop.

TIMESTAMPS
0:00 — Cold Open.
1:41 — Sponsor: Hume Body Pod.
2:53 — Intro: The Cholesterol Paradox.
4:48 — How Statins Work.
5:36 — PCSK9 Targeting.
7:38 — How VERVE-102 Works.
9:16 — The Results.
12:16 — Other Drugs and Pricing.
15:12 — Natural Alternatives.
17:42 — Other One and Done Drugs.
18:40 — Longevity Latte.

SOURCES \& LINKS
NEJM paper (Vafai, Täubel, Patel, Kathiresan et al.): https://www.nejm.org/doi/full/10.1056…
Eli Lilly press release on Phase 1 Heart-2 data: https://www.prnewswire.com/news-relea…
ClinicalTrials.gov Heart-2 trial entry (NCT06164730): https://clinicaltrials.gov/study/NCT0…
Verve Therapeutics FDA Fast Track designation announcement: https://vervetx.gcs-web.com/news-rele…
Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): https://www.nejm.org/doi/abs/10.1056/.…
Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: • Dave Ricks, CEO of Eli Lilly, on GLP-1s an…

Jacque Fresco: Apply the Methods of Science to the Social System!

I have to confess something about this interview.

I really liked Jacque Fresco. Not as a thinker I was supposed to admire, but as a person: the humor, the humility, the scientific curiosity still burning at 97.

That made the disagreements harder, not easier.

Fresco spent almost a century arguing one idea. We apply the methods of #science to engineering, to medicine, to flight. Then we run our economies and our politics on opinion, tradition, and the preferences of the financial elite.

He thought we had it exactly inverted. Rigor for the machines, guesswork for the humans.

“Technology was never the hard part. The harder question is what kind of society we want it to serve.”

Continue reading “Jacque Fresco: Apply the Methods of Science to the Social System!” | >

John Nash (1928−2015)

John Nash was born on June 13, 1928, in Bluefield, West Virginia, a former coal town nestled deep in the Appalachian Mountains. As a young boy, Nash was solitary, bookish, and introverted. His father, John Sr., was a quiet engineer with an incisive mind. His mother, Virginia, also intelligent, was a former teacher who had large dreams for her son, pushing him to read at four, learn Latin, and skip a grade at school.

The first hint of John Nash’s math talent came in fourth grade, when a teacher told Virginia that the boy couldn’t do the math. Virginia laughed, well aware that her son was going down his own path to solve the simple problems. In high school, John solved his teachers’ clunky proofs in just a few elegant steps. He was one of ten nationally awarded winners of the George Westinghose Award, which provided him with a full scholarship to the Carnegie Institute of Technology. He hopped from engineering to chemistry before discovering his passion: mathematics.

He was accepted into Princeton University, which at the time was to mathematicians what Detroit was, and still is, to cars. Nash first wowed his peers with an elegantly playable board game, which his peers dubbed “Nash,” but later reached the market as Hex. He then absorbed himself in one of the sexiest math fields of the day, game theory, which described strategies in competition, whether in card games or business. His deceptively simple doctoral thesis would later re-orient the field of economics, although no one, not even Nash, predicted its potential.

Toward cheaper, cleaner hydrogen production

Sobek was born and raised in Argentina, but he also grew up at MIT over the course of three degrees and more than a decade. He first studied aeronautics and astronautics at MIT, then jumped to mechanical engineering as a graduate student, then moved to the Department of Electrical Engineering and Computer Science, where he worked under PhD advisors and MIT professors Martha Gray and Stephen Senturia. His thesis focused on a technique for quickly measuring optical properties of large numbers of biological cells.

“A lot of my learnings around microfabrication and materials chemistry ended up being really relevant for 1s1,” Sobek says. “A class that was very important to me was taught by Professor Amar Bose. I was a teaching assistant for him for a couple of semesters, and that had an incredible influence on my thinking.”

Following graduation, Sobek worked in microelectronics and microfluidics before founding his own company, Zymera, in 2004. The company developed deep-tissue imaging technology for detecting cancer and other serious diseases.

/* */